Overview

XKH001 Injection in Healthy Subjects

Status:
Not yet recruiting

Trial end date:
2024-12-01

Target enrollment:

Participant gender:

Summary

This study is a randomized, double-blind, placebo-controlled, multiple ascending dose (MAD) clinical study. The primary objective is to evaluate the safety, tolerability, and PK of multiple SC doses of XKH001 in healthy subjects.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Beijing Kanova Biopharmaceutical Co., LTD